Aligos Therapeutics, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Aligos Therapeutics entered an exclusive license agreement with Xiamen Amoytop Biotech Co., Ltd. to develop and commercialize pevifoscorvir sodium in Greater China for chronic HBV infection. Aligos received $25M upfront and is entitled to up to $420M in clinical, regulatory, and sales milestones with high single-digit royalties. The company also received a $3M milestone payment when Amoytop achieved IND approval in China for ALG-170675 (an ASO candidate). Cash position declined from $77.8M (Dec 2025) to $30.4M (Jun 2026), though the $25M payment arrived in July 2026.
Why this rating
Amoytop deal ($25M upfront) is 126% of current market cap—materially strengthens cash runway. $420M milestone potential validates pipeline. However, company retains only ex-Greater China rights; runway extends only to Q4 2026 even with cash injection. Clinical progress (B-SUPREME enrollment complete) is encouraging but not yet proven efficacy.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.